Targeting Protein Aggregation in ALS
Michele Perni1,2, Benedetta Mannini3,4
1Baz-Therapeutics Inc., 810 Rittenhouse Square, Suite 412, Philadelphia, PA 19103, USA.
Abstract:
Proteinopathies involve the abnormal accumulation of specific proteins. Maintaining the balance of the proteome is a finely regulated process managed by a complex network of cellular machinery responsible for protein synthesis, folding, and degradation. However, stress and ageing can disrupt this balance, leading to widespread protein aggregation. Currently, several therapies targeting protein aggregation are in clinical trials for ALS. These approaches mainly focus on two strategies: addressing proteins that are prone to aggregation due to mutations and targeting the cellular mechanisms that maintain protein homeostasis to prevent aggregation. This review will cover these emerging drugs. Advances in ALS research not only offer hope for better outcomes for ALS patients but also provide valuable insights and methodologies that can benefit the broader field of neurodegenerative disease drug discovery.
Insights
Proteinopathies, like those in Amyotrophic Lateral Sclerosis (ALS), involve protein aggregation. Emerging therapies target aggregation-prone proteins or cellular mechanisms to restore proteostasis, offering hope for neurodegenerative disease treatment.
Area of Science:
- Neuroscience
- Molecular Biology
- Biochemistry
Background:
- Proteinopathies are characterized by the abnormal accumulation of specific proteins within cells.
- Cellular proteostasis, the balance of protein synthesis, folding, and degradation, is crucial for health but can be disrupted by stress and aging.
- This disruption leads to widespread protein aggregation, a hallmark of many neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS).
Purpose of the Study:
- To review emerging drugs and therapeutic strategies for proteinopathies in the context of ALS.
- To highlight two main therapeutic approaches: targeting mutation-prone proteins and enhancing cellular protein homeostasis mechanisms.
- To discuss the broader implications of ALS research for neurodegenerative disease drug discovery.
Main Methods:
- Literature review of current clinical trials and research in ALS therapeutics.
- Analysis of therapeutic strategies focusing on protein aggregation and proteostasis.
- Synthesis of findings to provide insights into drug discovery for neurodegenerative diseases.
Main Results:
- Several therapeutic strategies targeting protein aggregation are currently in clinical trials for ALS.
- These strategies are broadly categorized into targeting specific aggregation-prone proteins and enhancing cellular protein homeostasis.
- Advances in ALS research are yielding valuable insights applicable to other neurodegenerative conditions.
Conclusions:
- Emerging therapies for ALS show promise for improving patient outcomes.
- Understanding and manipulating protein homeostasis is a key strategy in combating proteinopathies.
- ALS research contributes significantly to the broader field of neurodegenerative disease drug discovery.
More Related Videos
11:12Assay Development for High Content Quantification of Sod1 Mutant Protein Aggregate Formation in Living Cells
Published on: October 4, 2017
09:16Exogenous Administration of Microsomes-associated Alpha-synuclein Aggregates to Primary Neurons As a Powerful Cell Model of Fibrils Formation
Published on: June 26, 2018
